Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer
Status:
Withdrawn
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
IMGN853 is designed to inhibit cell division and cell growth of folate receptor 1
(FRĪ±)-expressing tumor cells. The purpose of this study is to test the safety of IMGN853 and
bevacizumab and see what effects (good and bad) that this combination treatment has on
subjects with recurrent endometrial cancer.